SCHEMBL2087963

SCHEMBL2087963

Cc1cccc(C(=O)c2cn3cc(Cl)ccc3n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
ENPP3 O14638 1/20 0.44
ALPL P05186 1/20 0.44
XIAP P98170 1/20 0.44
CNR2 P34972 1/20 0.44
EGLN1 Q9GZT9 2/20 0.43
RAB9A P51151 4/20 0.43
KDM4E B2RXH2 4/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NR4A2 P43354 2/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
STAT3 P40763 1/20 0.43
STAT1 P42224 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242240 0.89 EGLN1 (0.53) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL2087864 0.86 HRH4 (0.46) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL4211423 0.85 RAB9A (0.53) HRH4HRH3CNR2EGLN1RAB9A
SCHEMBL2086752 0.83 HRH4 (0.54) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL4213158 0.82 HRH4 (0.55) HRH4HRH3CNR2EGLN1RAB9A
SCHEMBL4243985 0.80 HRH4 (0.48) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL4250022 0.78 HRH4 (0.49) HRH4HRH3EGLN1RAB9AKDM4E
SCHEMBL4220034 0.78 HRH4 (0.48) HRH4HRH3CNR2EGLN1RAB9A
SCHEMBL2086757 0.77 RAB9A (0.52) HRH4HRH3ENPP3ALPLXIAP
SCHEMBL2086534 0.77 HRH4 (0.50) HRH4HRH3EGLN1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US claimed
US-7902219-B2 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-08 US disclosed
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143420-A1 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF NR4A2, NR4A3, NCOR1 HRH4 250/4885HRH3 241/4885ENPP3 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.